Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $127.44

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned an average rating of “Moderate Buy” from the nineteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $126.00.

Several research firms recently weighed in on BNTX. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Citigroup cut their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $128.00 to $105.00 in a research note on Tuesday. Finally, UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th.

BioNTech Stock Down 1.8%

Shares of NASDAQ BNTX opened at $96.40 on Tuesday. The stock has a market capitalization of $24.38 billion, a price-to-earnings ratio of -12.31 and a beta of 1.29. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The firm has a 50-day moving average price of $97.00 and a 200 day moving average price of $95.37. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s quarterly revenue was down 59.5% on a year-over-year basis. During the same period last year, the business posted ($1.60) earnings per share. Equities research analysts anticipate that BioNTech will post -6.33 EPS for the current fiscal year.

Insider Buying and Selling at BioNTech

In other news, CEO Ugur Sahin sold 45,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00. Following the completion of the transaction, the chief executive officer directly owned 813,209 shares of the company’s stock, valued at $83,638,545.65. This trade represents a 5.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 149,500 shares of company stock worth $15,079,610. Company insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. Larson Financial Group LLC lifted its position in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. EFG International AG purchased a new stake in BioNTech during the 4th quarter worth about $29,000. Caitong International Asset Management Co. Ltd increased its position in BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in BioNTech in the 2nd quarter valued at about $39,000. Finally, Tower Research Capital LLC TRC raised its stake in BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.